Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 12/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15467717 | 1.00 | PDE2A (0.38) | PDE2ATRPM8HDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL15568022 | 0.99 | PDE2A (0.37) | PDE2ATRPM8HDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL16413785 | 0.99 | PDE2A (0.37) | PDE2ATRPM8HDAC3HDAC1HDAC2 | |
| SCHEMBL16418760 | 0.91 | TRPM8 (0.35) | PDE2ATRPM8CTNNB1WNT3AAKT1 | |
| Hydrochloric Acid SCHEMBL15567327 | 0.90 | TRPM8 (0.35) | PDE2ATRPM8CTNNB1WNT3AAKT1 | |
| Hydrochloric Acid SCHEMBL15567326 | 0.90 | TRPM8 (0.35) | PDE2ATRPM8CTNNB1WNT3AAKT1 | |
| SCHEMBL15467665 | 0.87 | TRPM8 (0.35) | TRPM8CTNNB1WNT3AAKT1AKT2 | |
| SCHEMBL15467667 | 0.87 | TRPM8 (0.35) | TRPM8CTNNB1WNT3AAKT1AKT2 | |
| SCHEMBL15467331 | 0.85 | PDE2A (0.38) | PDE2ATRPM8HDAC3HDAC1HDAC2 | |
| SCHEMBL15469414 | 0.84 | TRPM8 (0.33) | TRPM8CTNNB1WNT3AAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | PDE2A 891/4885TRPM8 1/4885HDAC3 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.